Hutchison China Meditech Limited Chi-Med to Present HMPL-689 Clinical Data at ASH
November 05 2020 - 3:00AM
RNS Non-Regulatory
TIDMHCM
Hutchison China Meditech Limited
05 November 2020
Press Release
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the
62(nd) ASH Annual Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November
5, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM:
HCM) today announces that initial analysis of the first in human
HMPL-689 Phase I dose escalation study will be presented as a
poster at the upcoming 62(nd) American Society of Hematology (ASH)
Annual Meeting and Exposition, taking place on December 5-8, 2020
virtually.
Further details of the presentation are as follows:
Title: Results from a Phase 1 Dose Escalation Study of HMPL-689,
a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor,
in Chinese Patients with Relapsed/Refractory (R/R)
Lymphoma
Lead Author: Junning Cao, Fudan University Cancer Center, Shanghai,
China
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell
Lymphoma - Clinical Studies: Poster I
Abstract # #1135 / https://doi.org/10.1182/blood-2020-136013
/ Link:
Date & Time: Saturday, December 5, 2020, 7:00 AM - 3:30 PM (PT)
About HMPL-689
HMPL-689 is a novel, selective oral inhibitor targeting the
isoform PI3K , a component in the B-cell receptor signaling
pathway. HMPL-689's pharmacokinetic ("PK") properties are favorable
with good oral absorption, moderate tissue distribution and low
clearance in preclinical PK studies, we therefore anticipate low
risk of drug accumulation and drug-to-drug interaction.
Our Phase I/Ib study of HMPL-689 in China has successfully
established a Phase II dose and has now expanded into multiple
sub-categories of indolent non-Hodgkin's lymphoma. We have
initiated a Phase I/Ib study in the U.S. and Europe, with patient
enrollment underway.
Chi-Med currently retain all rights to HMPL-689 worldwide.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
HMPL-689, the further clinical development for HMPL-689, its
expectations as to whether such studies would meet their primary or
secondary endpoints, and its expectations as to the timing of the
completion and the release of results from such studies.
Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions
regarding enrollment rates, timing and availability of subjects
meeting a study's inclusion and exclusion criteria, changes to
clinical protocols or regulatory requirements, unexpected adverse
events or safety issues, the ability of drug candidates HMPL-689,
including as a combination therapies, to meet the primary or
secondary endpoint of a study, to obtain regulatory approval in
different jurisdictions, to gain commercial acceptance after
obtaining regulatory approval, the potential market of HMPL-689 for
a targeted indication and the sufficiency of funding. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPGMWGUPUURA
(END) Dow Jones Newswires
November 05, 2020 04:00 ET (09:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024
